GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study

Affiliations

¹ University of California, Riverside, School of Medicine, Riverside, California, USA.
² University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas, USA.
³ University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
⁴ University of Hawaii at Manoa, John A. Burns School of Medicine, Honolulu, Hawaii, USA.
⁵ Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁶ Division of Dermatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
⁷ David Geffen School of Medicine at the University of California, Los Angeles, California, USA.

Peichi P Chou et al. J Eur Acad Dermatol Venereol. 2025.

. 2025 Jul 22.

doi: 10.1111/jdv.20874. Online ahead of print.

¹ University of California, Riverside, School of Medicine, Riverside, California, USA.
² University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas, USA.
³ University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
⁴ University of Hawaii at Manoa, John A. Burns School of Medicine, Honolulu, Hawaii, USA.
⁵ Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁶ Division of Dermatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
⁷ David Geffen School of Medicine at the University of California, Los Angeles, California, USA.

No abstract available

Keywords: cardiovascular disease; diabetes mellitus; glucagon‐like peptide‐1 receptor; hidradenitis suppurativa; metabolic disease; obesity.

References

1. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058.
1. Bui TL, Silva‐Hirschberg C, Torres J, Armstrong AW. Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta‐analysis. J Am Acad Dermatol. 2018;78(2):395–402.
1. Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018;32(1):129–144.
1. Kromann C, Ibler KS, Kristiansen V, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553–557.
1. Kromann C, Ibler KS, Kristiansen V, Jemec GB. Obesity and hidradenitis suppurativa: targeting meta‐inflammation for therapeutic gain. Clin Exp Dermatol. 2023;48(9):984–990.